Rising Star Buy: Amyris Biotechnologies

This article is part of our Rising Star Portfolios series. Sean is co-manager of the Dada Portfolio.

I'm taking the plunge, guys. Last week I talked about why I was considering Amyris Biotechnologies (Nasdaq: AMRS  ) for the Dada Portfolio. To recap:

  • Its very cool technology can transform yeast into microfactories capable of producing almost any biological molecule.
  • It's already successfully produced artemisinin, an antimalarial drug.
  • It's currently focused on Biofene, an alternative petroleum replacement that Amyris can produce from Brazilian sugarcane

The potential for Amyris's technology is huge. Not only does the company envision Biofene as a "No Compromise" replacement for diesel and jet fuel, but it's also signing deals with Procter & Gamble (NYSE: PG  ) and other manufacturers to use Biofene in consumer products. And even beyond that fuel, Amyris has a platform technology with the potential to create many different types of target molecules that may be of value to society.

Oh, the risks!
That said, the perils here are substantial. While the company has grown revenue more than 11-fold in just the past three years, it has also never been profitable. That's not entirely unexpected, considering that this is a relatively early-stage company that's still working out the kinks in commercializing its product. We'd expect to see that figure flip around once Amyris reaches some sort of manufacturing scale in the coming years.

Still, it means that for now, the company's bleeding cash. Since 2007, it has spent almost $200 million. With the recent IPO, Amyris now sits on $259 million in net cash, a decent-sized cushion to sustain the company over the critical next few years.

So why are we buying?
Amyris is targeting 2011 and 2012 as vital milestones in its plans to begin commercially manufacturing its products. We're definitely very early to this story, but we think it's important to get our feet wet. We're looking at this from an almost venture capitalist position. The most we can lose on this position is, well, 100% -- just like any other company. But what's the most we can gain? 300, 400, 500%? That and more are possible as well.

The spectrum of potential outcomes is very wide with this stock. But that's also why we don't plan on initially putting a lot of capital at risk. Our target allocation is just $300, or about 2% of the Dada Portfolio's total investable cash by year's end. For $300, we get essentially a call option on what could be a meteoric stock, as well as a foot in the door to better watch the story and follow the industry.

Is this Foolish, or just plain foolish? Leave us a comment here or on our discussion boards, and let us know what you think.

Learn more about Dada
Visit our Foolsaurus page here to find out more about the Dada Portfolio, and keep an eye on our Twitter page @TMFDada for updates.

The Dada Portfolio is a part of the Rising Star series of real money portfolios. It is co-managed by Sean Sun and Ilan Moscovitz.

Sean owns shares of Procter & Gamble. Procter & Gamble is a Motley Fool Income Investor pick. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Read/Post Comments (0) | Recommend This Article (11)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 1430401, ~/Articles/ArticleHandler.aspx, 10/23/2016 2:25:36 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 1 day ago Sponsored by:
DOW 18,145.71 -16.64 -0.09%
S&P 500 2,141.16 -0.18 -0.01%
NASD 5,257.40 15.57 0.30%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

10/21/2016 4:00 PM
AMRS $1.11 Up +0.04 +3.74%
Amyris CAPS Rating: **
PG $84.33 Down -0.60 -0.71%
Procter and Gamble CAPS Rating: ****